While this is for prostate cancer it seems that the technology could be useful across the board. We’ll just have to wait and see.
A new imaging device, ei•Nav/Artemis TM, now officially cleared by the U.S. Food and Drug Administration (FDA), offers urologists breakthrough technology that will significantly help in the fight against prostate cancer. Artemis, designed by Eigen, a Northern California-based company known for developing innovative, affordable medical imaging solutions, was introduced at the American Urological Association’s (AUA) annual meeting May 17 - 22 in Orlando, FL.
“Since prostate cancer strikes a staggering one in six men, it is startling to me that until now blind biopsies have been the standard of care once cancer of the prostate is suspected,” said Eigen CEO Michael Castorino. “Artemis is intended to give the nation’s nearly 10,000 urologists the technology to navigate to a desired location for prostate biopsy and record this information for future reference, treatment planning and monitoring.”
While this is for prostate cancer it seems that the technology could be useful across the board. We’ll just have to wait and see.
A new imaging device, ei•Nav/Artemis TM, now officially cleared by the U.S. Food and Drug Administration (FDA), offers urologists breakthrough technology that will significantly help in the fight against prostate cancer. Artemis, designed by Eigen, a Northern California-based company known for developing innovative, affordable medical imaging solutions, was introduced at the American Urological Association’s (AUA) annual meeting May 17 - 22 in Orlando, FL.
“Since prostate cancer strikes a staggering one in six men, it is startling to me that until now blind biopsies have been the standard of care once cancer of the prostate is suspected,” said Eigen CEO Michael Castorino. “Artemis is intended to give the nation’s nearly 10,000 urologists the technology to navigate to a desired location for prostate biopsy and record this information for future reference, treatment planning and monitoring.”
More: www.eigen.com